STOCK TITAN
  1. Home
  2. News
  3. ZIVO

Zivo Bioscience Inc - ZIVO STOCK NEWS

Welcome to our dedicated news page for Zivo Bioscience (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zivo Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zivo Bioscience's position in the market.

News
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
Rhea-AI Summary
Zivo Bioscience, Inc. announces positive findings from a 42-day coccidiosis challenge study, demonstrating the impact of its product on broiler production. The product reduces intestinal damage caused by the Eimeria parasite, leading to improved feed utilization and a better Feed Conversion Ratio (FCR), which drives profitability. These results position ZIVO's product as a potential game-changer in the poultry industry, offering improved outcomes at cost parity or better.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
-
News
ZIVO Bioscience Announces Uplisting to OTCQB Market
Rhea-AI Summary
Zivo Bioscience, Inc. (ZIVO) has successfully uplisted its common stock from the OTC Pink Market to the OTCQB Venture Market, under the ticker symbol 'ZIVO'. This move is aimed at enhancing visibility, improving market access, and increasing liquidity for shareholders. The OTCQB listing requires compliance with higher standards, financial reporting with the SEC, minimum bid price test, audited financials, and company verification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
News
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Rhea-AI Summary
Zivo Bioscience, Inc. announces positive results from a 42-day coccidiosis challenge study, demonstrating the effectiveness of its immune-modulating treatment for broiler chickens. The study showed that the product candidate is comparable to a market-leading anticoccidial product containing antibiotics and chemicals. Zivo will pursue a partnership with a global animal health company for commercializing its coccidiosis product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.74%
Tags
none
News
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Rhea-AI Summary
Zivo Bioscience, Inc. is conducting a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The study aims to confirm the positive effects of Zivo's non-antibiotic alternative, including reduced mortality and improved bird growth rates. The study will also analyze secondary benefits such as protection of intestinal tissue and reduction of pathogenic bacteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
News
ZIVO Bioscience Announces Reverse Stock Split
Rhea-AI Summary
Zivo Bioscience announces a 1-for-6 reverse stock split to regain compliance with Nasdaq listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
433.33%
Tags
none
-
News
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Rhea-AI Summary
Zivo Bioscience, Inc. announces participation in the 8th Annual Dawson James Small Cap Growth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.94%
Tags
conferences
News
Trial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
Rhea-AI Summary
ZIVO Bioscience announces positive results from coccidiosis trial in broiler chickens, demonstrating statistically significant improvements in broiler health. The product candidate showed potential to mitigate the effects of coccidiosis through a non-antibiotic mechanism of action. ZIVO plans to launch the final phase of validation with results expected by the end of 2023. The company remains confident in the stability and effectiveness of its product candidate, presenting a disruptive solution to coccidiosis in the poultry industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
-
News
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
Rhea-AI Summary
Zivo Bioscience, Inc. announces that ZWorldwide, its exclusive distributor in North America, will purchase the entire supply of Zivolife for the first 18 months. ZWorldwide has also committed to purchasing at least 24,000 kilograms of product for each of the next five years. ZIVO is collaborating with Alimenta Algae to increase production volumes and expects a new facility to be fully operational in 2025, capable of producing up to 100,000 kilograms of dried product per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
News
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
Rhea-AI Summary
Zivo Bioscience announces commercialization of proprietary algal biomass as food ingredient. Signs distribution agreement with ZWorldwide for branded DTC sales of ZivolifeTM. Also signs manufacturing agreement with Alimenta Algae to grow and process algal biomass. ZivolifeTM is the company's first revenue-generating product. Global food and beverage microalgae market projected to reach $247 million by 2033. ZivolifeTM is natural, non-GMO, and a source of plant-based protein, beta glucan, and fiber.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
News
ZIVO Bioscience Announces Pricing of $4.0 Million Registered Direct Offering Priced At-The-Market
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.09%
Tags
offering
Stock ZIVO logo
Zivo Bioscience Inc

OTC:ZIVO

ZIVO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ZIVO Stock Data

22.22M
1.66M
40.58%
0.08%
2.04%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Keego Harbor

About ZIVO

zivo bioscience, inc., a u.s.-based r&d firm, is dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains.